Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity.

Next Previous
X
Search
Trial Profile

The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acipimox (Primary)
  • Indications Hypertriglyceridaemia; Insulin resistance; Obesity
  • Focus Pharmacodynamics

    • Most Recent Events

    • 01 Mar 2016 Biomarkers information updated
    • 23 May 2012 Actual initiation date 1 May 2012 added as reported by ClinicalTrials.gov.
    • 23 May 2012 Planned end date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top